DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Study to Evaluate Efficacy and Tolerability of Micardis®/Micardis® Plus in Patients With Hypertension

Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Micardis® (Drug); Micardis® Plus (Drug)

Phase: N/A

Status: Completed

Sponsored by: Boehringer Ingelheim

Summary

Study to evaluate efficacy and tolerability of Micardis/Micardis Plus under usual daily-practice prescribing conditions in hypertensive patients

Clinical Details

Official title: Post-Marketing Surveillance Study Micardis Plus

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: Change in morning blood pressure (office and self-measured)

Secondary outcome:

Change in heart rate

Number of patients with adverse drug reactions

Assessment of efficacy by investigator on a 5-point scale

Assessment of tolerability by investigator on 5-point scale

Change in rate of morning complaints

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Males and females for whom a medical antihypertensive therapy is indicated

- Age >= 18 years

Exclusion Criteria:

- Age < 18 years

Locations and Contacts

Additional Information

Starting date: January 2003
Last updated: September 16, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017